Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.45M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.09M

Average 0.22M

Returns on capital

Nyxoah S.A. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-183.4%

avg -112.1%

ROIC

-88.9%

avg -49.1%

ROA

-76.1%

avg -43.8%

Analysis

ROA is currently the strongest return metric at -76.1% versus its period average of -43.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Bruno Onkelinx

Chief Technical OfficerEUR 1.68M54——

Liam J. Kelly

Chief Executive OfficerEUR 978.01K59——

Olivier Taelman

Chief Executive OfficerEUR 978.01K54——

Loic Moreau

President of International & Interim CFOEUR 526.53K46——

Robert Taub

Co-Founder & ChairmanEUR 133.2K79——

Ashlea Mittelstaedt

Chief Strategy Officer————

Geeta Kaveti

Chief Compliance Officer————

Pearson Dennis

Investor Relations Associate————

Maurits S. Boon

Chief Medical Officer————

Jeyakumar Subbaroyan

Chief Science Officer————

John Landry

Chief Financial Officer—53——

Remi Renard

Head of Investor Relations & Corporate Communication————

Scott Holstine

Chief Commercial Officer—55——

An Moonen

General Counsel————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+48.1%
+93.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +48.1% over three years. Forward estimates point to Revenue at +93.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Nyxoah S.A. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NYXH's management, answered from reported figures.

Who manages NYXH?

Nyxoah S.A. (NYXH) lists 14 active executives. The top listed executive is Liam J. Kelly, Chief Executive Officer.